Document is current
Any future updates will be listed below
-
Authors
Herran, Reid https://orcid.org/0000-0002-4833-0290
Wilcox, Samuel
Hodish, Gal https://orcid.org/0009-0003-7352-9503
Hassan, Syed A.
Mertens, Haley
Almario, Christopher V.
Gu, Philip https://orcid.org/0000-0003-4819-8979
Kayal, Maia https://orcid.org/0000-0002-9640-950X
Cohen-Mekelburg, Shirley
Regal, Randolph E. https://orcid.org/0000-0001-7984-9338
Bishu, Shrinivas https://orcid.org/0000-0003-4823-5805
Siegel, Corey A. https://orcid.org/0000-0002-2240-6605
DeJonckheere, Melissa
Higgins, Peter D. R.
Berinstein, Jeffrey A.
- License Information
-
More Information
Article History
Received: 3 April 2026
Accepted: 30 May 2026
First Online: 24 June 2026
Declarations
:
: JAB participated on an advisory board for AbbVie and Boehringer Ingelheim Health. PDRH received consulting fees from AbbVie, Amgen, Buhlmann Laboratories, Celltrion, Curacle, Genentech, and Eli Lilly. CAS received consulting fees from AbbVie, Boomerang, Celltrion, Johnson and Johnson, Lilly, Pfizer, Sanofi, Takeda; speaker fees for CME activities for AbbVie, Johnson and Johnson, Lilly, Pfizer, Takeda; grant support from AbbVie, Celltrion, Johnson and Johnson, Lilly, Pfizer, Takeda; licensing fees from Takeda. All other authors report no disclosures.
: The University of Michigan Institutional Review Board (IRBMED) approved this study.
: Informed consent was obtained from all participants included in this study.
